Studies on the Action Mechanism of the Antihemostatic Effect of lodopeptides^[*]

Summary

A synthetic iodopeptide having a glutamic acid-diiodotyrosine molar ratio of 1:1 has been shown to be an effective anticoagulant both in vivo and in vitro. Contrasted with heparin the following general conclusions may be made regarding its action. The iodopeptide does not act through the inactivation of thrombin in plasma. Iodopeptide does interact with fibrinogen to form a complex which, in vitro, is not soluble in buffered saline at physiological pH. At pH 8, iodopeptide interacts with fibrinogen to form a soluble complex in the presence of 0.9 % NaCl that is not coaguable either by thrombin or Crotalus venom enzymes. All the available evidence indicates that the fibrinogen to fibrin conversion is not inhibited under these conditions, but that fibrin, once formed, is not able to polymerize due to interference by iodopeptide. Similar results were obtained with heparin in vitro with thrombin-fibrinogen mixtures in the absence of NaCl.

Studies with Russell’s viper venom in native PRP strongly suggest that the iodopeptide also interferes with processes in the early coagulation pathway associated with prothrombin activation.

^* This paper is dedicated to Professor Karl H. Slotta, on the occasion of his 80th birthday.

• References

• 1 Berger A, Noguchi J, Katchalski E. 1956; Poly-L-cysteine. Journal of the American Chemical Society 78: 4483.
• 2 Biggs R. (ed.) 1972. Human Blood Coagulation, Hemostasis and Thrombosis. Blackwell Scientific Publications; Oxford: 327.
• 3 Deutsch E. 1971. Klinische Anwendung der Anticoagulantien. In: Markwardt R. (ed.) Handbuch der Experimentellen Pharmakologie. XXVII Anticoagulantien. Springer-Verlag; Berlin: 302.
• 4 Ferry J. D, Morrison P. R. 1974; Preparation and properties of serum and plasma proteins. VIII. The conversion of human fibrinogen to fibrin under various conditions. Journal of the American Chemical Society 69: 388.
• 5 Findlay J. B. C, Brew K. 1972; The complete amino acid sequence of human α-lactalbumin. European Journal of Biochemistry 27: 65.
• 6 Friedman E, Gill III T. J, Doty P. 1961; Studies on synthetic polypeptide antigens. III. synthesis and physico-chemical properties of a group of linear-chain antigens. Journal of the American Chemical Society 83: 4050.
• 7 Godal H. C. 1960; Precipitation of human fibrinogen with heparin. Scandinavian Journal of Clinical and Laboratory Investigation 12: 56.
• 8 Godal H. C. 1961; a Binding of heparin to fibrin(ogen). Scandinavian Journal of Clinical and Laboratory Investigation 13: 550.
• 9 Godal H. C. 1961; b The influence of heparin on the fibrin clot. Scandinavian Journal of Clinical and Laboratory Investigation 13: 306.
• 10 Katchalski E, Sela M. 1953; The synthesis and spectrophotometrie study of poly-L-tyrosine and poly-3-5-diiodotyrosine. Journal of the American Chemical Society 75: 5284.
• 11 Laki K. 1951; The polymerization of proteins: the action of thrombin on fibrinogen. Archives of Biochemistry and Biophysics 32: 317.
• 12 Martin C. J, Golubow J, Axelrod A. E. 1959; The hydrolysis of carbobenzoxy-L-tyrosine p-nitrophenyl ester by various enzymes. The Journal of Biological Chemistry 234: 1718.
• 13 Mende T. J. 1970; Anticoagulant activity of synthetic iodinated polypeptides. Pharmacology 4: 309.
• 14 Miale J. B, Mende T. J. 1971; A synthetic iodinated polypeptide that inhibits polymerization of fibrinogen. Blut 22: 76.
• 15 Seegers W. H, Smith H. P. 1942; Factors which influence the activity of purified thrombin. American Journal of Physiology 137: 348.
• 16 Sherry S, Troll W. 1954; The action of thrombin on synthetic substrates. The Journal of Biological Chemistry 208: 95.
• 17 Stewart J. M, Young J. D. 1969. Solid Phase Peptide Synthesis. W. H. Freeman and Company; San Francisco: 38.